Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2019/059542, filed Nov 1, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,738,067 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) In force · High confidence | Medic Life Sciences, Inc. | In force | High confidence | ||
| US 12,240,869 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) In force · Medium confidence | Medic Life Sciences, Inc. | In force | Medium confidence | ||
| Application 19/037,690 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) Pending Not granted | Medic Life Sciences, Inc. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Medic Life Sciences, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.